3B BLACKBIO DX
|
3B BLACKBIO DX Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 69.94 | 55.66 | 37.46 | 30.28 | 42.98 |
| CEPS(Rs) | 75.92 | 56.93 | 38.70 | 31.28 | 43.88 |
| DPS(Rs) | 5.00 | 4.00 | 3.00 | 2.50 | 10.50 |
| Book NAV/Share(Rs) | 378.58 | 313.27 | 260.32 | 225.60 | 204.26 |
| Tax Rate(%) | 22.14 | 25.48 | 27.59 | 26.54 | 25.50 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 40.00 | 51.94 | 44.49 | 47.08 | 46.00 |
| EBIT Margin(%) | 54.40 | 66.45 | 59.98 | 57.42 | 53.73 |
| Pre Tax Margin(%) | 54.24 | 66.34 | 59.81 | 57.10 | 53.60 |
| PAT Margin (%) | 42.23 | 49.44 | 43.31 | 41.94 | 39.93 |
| Cash Profit Margin (%) | 45.84 | 50.56 | 44.73 | 43.34 | 40.76 |
| Performance Ratios | |||||
| ROA(%) | 17.79 | 17.54 | 13.89 | 12.77 | 16.70 |
| ROE(%) | 20.22 | 19.41 | 15.42 | 14.98 | 22.59 |
| ROCE(%) | 25.90 | 26.03 | 21.21 | 20.24 | 29.92 |
| Asset Turnover(x) | 0.42 | 0.35 | 0.32 | 0.30 | 0.42 |
| Sales/Fixed Asset(x) | 5.51 | 6.63 | 5.26 | 4.74 | 7.17 |
| Working Capital/Sales(x) | 0.91 | 0.85 | 0.70 | 0.62 | 1.25 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.18 | 0.15 | 0.19 | 0.21 | 0.14 |
| Receivable days | 111.38 | 137.66 | 172.80 | 188.65 | 146.56 |
| Inventory Days | 34.87 | 32.48 | 40.55 | 45.68 | 27.85 |
| Payable days | 45.25 | 42.09 | 61.16 | 70.42 | 37.45 |
| Valuation Parameters | |||||
| PER(x) | 16.10 | 29.05 | 20.54 | 13.73 | 7.94 |
| PCE(x) | 14.83 | 28.40 | 19.89 | 13.29 | 7.78 |
| Price/Book(x) | 2.97 | 5.16 | 2.96 | 1.84 | 1.67 |
| Yield(%) | 0.44 | 0.25 | 0.39 | 0.60 | 3.08 |
| EV/Net Sales(x) | 6.11 | 13.65 | 8.07 | 4.83 | 2.84 |
| EV/Core EBITDA(x) | 10.53 | 20.20 | 13.14 | 8.22 | 5.21 |
| EV/EBIT(x) | 11.23 | 20.54 | 13.45 | 8.42 | 5.29 |
| EV/CE(x) | 2.65 | 4.90 | 2.67 | 1.53 | 1.47 |
| M Cap / Sales | 6.80 | 14.36 | 8.90 | 5.76 | 3.17 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 47.11 | 30.14 | 19.87 | -23.32 | -64.43 |
| Core EBITDA Growth(%) | 26.29 | 43.24 | 25.14 | -17.34 | -71.22 |
| EBIT Growth(%) | 20.44 | 44.20 | 25.20 | -18.05 | -71.54 |
| PAT Growth(%) | 25.66 | 48.56 | 23.77 | -19.45 | -71.72 |
| EPS Growth(%) | 25.66 | 48.56 | 23.74 | -29.55 | -71.72 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.01 | - | - | 0.01 | 0.02 |
| Current Ratio(x) | 5.27 | 7.11 | 7.04 | 8.05 | 4.82 |
| Quick Ratio(x) | 4.77 | 6.64 | 6.56 | 7.49 | 4.38 |
| Interest Cover(x) | 325.63 | 590.84 | 357.08 | 178.97 | 407.23 |
| Total Debt/Mcap(x) | - | - | - | 0.01 | 0.01 |
Compare Financial Ratios of peers of 3B BLACKBIO DX
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| 3B BLACKBIO DX | ₹1,306.7 Cr | -5.4% | 5.1% | 16% | Stock Analytics | |
| LENSKART SOLUTIONS | ₹114,281.0 Cr | -3.6% | -5.2% | NA | Stock Analytics | |
| POLY MEDICURE | ₹16,207.7 Cr | -1% | -8.5% | -11.4% | Stock Analytics | |
| LAXMI DENTAL | ₹1,080.0 Cr | -0.5% | -3.2% | -40% | Stock Analytics | |
| PREVEST DENPRO | ₹467.9 Cr | -2.9% | -0.3% | -29.6% | Stock Analytics | |
| NURECA | ₹311.3 Cr | -1.7% | -4.2% | 43.1% | Stock Analytics | |
3B BLACKBIO DX Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| 3B BLACKBIO DX | -5.4% |
5.1% |
16% |
| SENSEX | -0.1% |
-2.3% |
-10.7% |
You may also like the below Video Courses
